At a global level, Teva has one of the broadest medicines pipelines in the industry, and in the UK Teva is one of the largest suppliers of medicines to the NHS.¹

That means we can be in a strong position to bring generic versions of branded medicines to market on the first day of patent protection ending. Generic medicines are typically sold at a substantially lower price to their branded medicine counterparts, as the development process is generally less costly.

Generic medicines bring significant savings to the NHS medicines bill – estimates are that generic medicines save the NHS over £13 billion every year, compared to the cost if their branded equivalents had been dispensed. This frees up valuable NHS budgets.